UBS Group Lowers Agios Pharmaceuticals (AGIO) to Market Perform

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by analysts at UBS Group from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, The Fly reports.

Other research analysts also recently issued research reports about the stock. Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price objective for the company in a research note on Tuesday, January 9th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, SunTrust Banks set a $80.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $77.64.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $0.40 during mid-day trading on Wednesday, reaching $76.53. 531,500 shares of the company traded hands, compared to its average volume of 838,608. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $82.96. The firm has a market cap of $4,285.58, a P/E ratio of -12.21 and a beta of 2.12.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. During the same period in the prior year, the company earned ($1.34) EPS. The company’s revenue was down 56.7% compared to the same quarter last year. equities analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current fiscal year.

In related news, insider Scott Biller sold 3,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $76.04, for a total transaction of $228,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David P. Schenkein sold 13,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.75, for a total transaction of $1,023,750.00. Following the sale, the chief executive officer now directly owns 13,000 shares of the company’s stock, valued at approximately $1,023,750. The disclosure for this sale can be found here. In the last three months, insiders have sold 183,114 shares of company stock valued at $13,866,025. Corporate insiders own 5.43% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. QS Investors LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agios Pharmaceuticals by 41.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 762 shares during the period. State of Alaska Department of Revenue purchased a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $160,000. Cubist Systematic Strategies LLC boosted its holdings in Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Agios Pharmaceuticals by 74.8% in the 4th quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 1,520 shares during the period. 82.74% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “UBS Group Lowers Agios Pharmaceuticals (AGIO) to Market Perform” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/02/14/ubs-group-lowers-agios-pharmaceuticals-agio-to-market-perform.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply